|

JBI-778 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Jubilant Therapeutics India Limited1

Indications

  • Adenoid Cystic Carcinoma of the Head and Neck1
  • Adenoid Cystic Carcinoma Metastatic1
  • NSCLC Patients With EGFR Activating Mutation1
  • Lung Cancer1
  • Cancer1

Other1 trial

First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.